Unichem Laboratories Limited (BOM:506690)
321.50
-9.00 (-2.72%)
At close: Mar 4, 2026
Unichem Laboratories Revenue
Unichem Laboratories had revenue of 5.21B INR in the quarter ending December 31, 2025, a decrease of -2.24%. This brings the company's revenue in the last twelve months to 22.14B, up 16.33% year-over-year. In the fiscal year ending March 31, 2025, Unichem Laboratories had annual revenue of 21.11B with 18.25% growth.
Revenue (ttm)
22.14B
Revenue Growth
+16.33%
P/S Ratio
1.03
Revenue / Employee
7.05M
Employees
3,142
Market Cap
22.77B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 21.11B | 3.26B | 18.25% |
| Mar 31, 2024 | 17.85B | 4.42B | 32.92% |
| Mar 31, 2023 | 13.43B | 731.90M | 5.76% |
| Mar 31, 2022 | 12.70B | 346.97M | 2.81% |
| Mar 31, 2021 | 12.35B | 1.31B | 11.91% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Morepen Laboratories | 17.87B |
| Hikal | 17.46B |
| Gufic Biosciences | 8.97B |
| Bliss GVS Pharma | 8.68B |
| TTK Healthcare | 8.30B |
| Lincoln Pharmaceuticals | 6.52B |
| Syncom Formulations (India) | 5.03B |
| Amrutanjan Health Care | 4.88B |
Unichem Laboratories News
- 5 months ago - Unichem Laboratories shares fall 3% after €19.49 million EU penalty demand in perindopril case - Business Upturn
- 6 months ago - Unichem Pharmaceuticals recalls mislabeled Cyclobenzaprine tablets in US over safety concerns - Business Upturn
- 6 months ago - Unichem Laboratories’ Roha API facility gets VAI classification from USFDA - Business Upturn
- 9 months ago - Unichem Laboratories shares drop 4% after USFDA flags 3 procedural issues at Roha facility - Business Upturn
- 10 months ago - Unichem Labs Q4 Results: Revenue up 27.9% YoY to Rs 587.18 crore, company swings back to net profit - Business Upturn
- 10 months ago - Unichem Laboratories receives USFDA EIR for Pithampur facility; inspection classified as VAI - Business Upturn
- 1 year ago - Unichem Laboratories shares rise 2.35% as API plant expansion boosts production capacity - Business Upturn
- 1 year ago - Unichem Laboratories completes Phase I expansion of API plant at Pithampur with Rs 200 crore investment - Business Upturn